Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neutrophil growth factors.

Jeffrey Crawford1

  • 1Duke University Medical Center, Box 3198, Room 25178, Morris Building, Durham, NC 27710, USA. crawf006@mc.duke.edu

Current Hematology Reports
|August 7, 2003
PubMed
Summary

Pegylated filgrastim (Neulasta) offers a sustained action, allowing once-per-cycle administration for chemotherapy patients. Clinical trials show it is equivalent to filgrastim and may reduce febrile neutropenia incidence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

Research square·2026
Same author

Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review.

Journal of cachexia, sarcopenia and muscle·2026
Same author

CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Future oncology (London, England)·2026
Same author

CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Corrigendum to "A review of relative dose intensity and survival in patients with metastatic solid tumors" [Crit. Rev. Oncol. Hematol. 93 (2015) 203-210].

Critical reviews in oncology/hematology·2026

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Pegylated filgrastim represents a significant advancement in neutrophil growth factor therapy.
  • Its sustained action allows for less frequent administration compared to traditional filgrastim.
  • Granulocyte colony-stimulating factor (G-CSF) plays a role in neutrophil regulation and inflammatory responses.

Purpose of the Study:

  • To evaluate the efficacy and safety of pegfilgrastim compared to filgrastim.
  • To investigate the pharmacokinetic and pharmacodynamic differences between the two agents.
  • To explore the potential anti-inflammatory role of G-CSF and its implications for pegfilgrastim's mechanism.

Main Methods:

  • Two randomized clinical trials were conducted.
  • Neutrophil kinetic studies were performed to analyze serum neutrophil levels.
  • Analysis included duration of severe neutropenia, absolute neutrophil count recovery, and incidence of febrile neutropenia.

Main Results:

  • Pegfilgrastim demonstrated equivalence to filgrastim in duration of severe neutropenia and neutrophil count recovery.
  • Secondary endpoints suggested a potential reduction in the incidence of febrile neutropenia with pegfilgrastim.
  • Neutrophil kinetic studies revealed steady serum levels with pegfilgrastim versus peak-and-trough effects with filgrastim.

Conclusions:

  • Pegfilgrastim is an effective and convenient alternative to filgrastim for managing chemotherapy-induced neutropenia.
  • Continuous G-CSF exposure from pegfilgrastim may enhance its anti-inflammatory effects.
  • Further research is needed to fully elucidate the mechanisms behind pegfilgrastim's enhanced benefits.

Related Experiment Videos